FIELD: medicine.
SUBSTANCE: invention relates to field of medicine, namely to methods of laboratory diagnostics and concerns method of amyloidosis diagnostics in patients with Alzheimer's disease and set of means for carrying out diagnostics. Method lies in determining quantity of monomer β-amyloid, where in tested aliquot oligomer β-amyloid formations are first dissociated to monomers. If difference of quantity of β-amyloid monomers in tested and control aliquots is determined, conclusion about amyloidosis presence is made. Application of method and set of means ensures high sensibility and specificity of amyloidosis diagnostics in patients with Alzheimer's disease.
EFFECT: ensuring high sensibility and specificity of amyloidosis diagnostics in case of Alzheimer's disease.
11 cl, 1 dwg, 2 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DIAGNOSTIC TECHNIQUE FOR AMYLOIDOSIS ACCOMPANYING ALZHEIMER'S DISEASE | 2011 |
|
RU2484471C1 |
| USING ANTI-AMYLOID BETA ANTIBODY IN OPHTHALMIC DISEASES | 2008 |
|
RU2604181C2 |
| PEPTIDE AND METHOD OF TREATMENT OF ALZHEIMER'S DISEASE | 2018 |
|
RU2679080C1 |
| PEPTIDE AND METHOD OF TREATMENT OF ALZHEIMER'S DISEASE | 2018 |
|
RU2679059C1 |
| HUMANISED ANTIBODY | 2008 |
|
RU2538709C2 |
| MONOCLONAL BODY AGAINST AMYLOID BETA | 2008 |
|
RU2571856C2 |
| HUMANISED ANTIBODY TO BETA AMYLOID | 2007 |
|
RU2498999C2 |
| HUMANIZED ANTIBODY TO BETA AMYLOID | 2013 |
|
RU2668161C2 |
| HUMANISED ANTIBODIES TO β-AMYLOID PEPTIDE | 2008 |
|
RU2475500C2 |
| APPLICATION OF ANTIBODY AGAINST AMYLOID-BETA IN CASE OF EYE DISEASES | 2008 |
|
RU2571859C2 |
